Clinical Trial Detail

NCT ID NCT02073123
Title Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors NewLink Genetics Corporation
Indications

melanoma

Therapies

Ipilimumab

Indoximod

Age Groups: adult

No variant requirements are available.